Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) - Part 2 on Triage, Treatment and Follow-up.

P. Hillemann, K. Friese, C. Dannecker, S. Klug, U. Seifert, T. Iftner, J. Hädicke, T. Loening, L. Horn, D. Schmidt, H. Ikenberg, M. Steiner, U. Freitag, U. Siebert, G. Sroczynski, W. Sauerbrei,
M. W. Beckmann, M. Gebhardt, M. Friedrich, K. Münstedt, A. Schneider, A. Kaufmann, K. U. Petry, A. PA Schäfer, M. Pawlita, J. Weis, A. Mehnert, M. Fehr, C. Grimm, O. Reich. M. Arbyn, J. Kleijn,
S. Wesselmann, M. Nothacker, M. Follmann, T. Langer, M. Jentschke


Annual opportunistic screening for cervical carcinoma has been done in Germany since 1971. The creation of this S3 guideline meets an important need, outlined in the National Cancer Plan, with regard to screening for cervical cancer, as this guideline aims to provide important information and support for planned organized screening for cervical cancer in Germany.


With the financial support of German Cancer Aid, 21 professional societies developed evidence-based statements and recommendations (classified using the GRADE system) for the screening, management and treatment of precancerous conditions of the cervix. Two independent scientific institutes compiled systematic reviews for this guideline.


The second part of this short summary deals with the triage, treatment and follow-up care of cervical dysplasia. With regard to those women who do not participate in screening, the guideline authors recommend sending out repeat invitation letters or an HPV self-collection kit. Colposcopy should be carried out for further investigation if cytology findings are Pap II-p and HPV test results are positive or if the results of an HPV 16 or HPV 18 screening test are positive. A single abnormal Pap smear should be triaged and investigated using HPV testing or p16/Ki67 dual staining.